Aceto acquisition of A&C

Industry: Health - Pharmaceutical research & manufacturing

Aceto acquisition of A&C
Announcement Date: Apr. 15, 2021

On Apr. 15, 2021, Aceto announced its acquisition of A&C. The transaction will help drive Aceto’s growth strategy, increasing its GMP (Good Manufacturing Practices) manufacturing, packaging and ingredients offerings for the cell culture, vaccine and biopharmaceutical industries, while also expanding its North American footprint. Aceto will continue to support A&C’s manufacturing facilities and offices in the U.S., Canada and Ireland. Financial terms were not disclosed.

Founded in 1947, Aceto is a global provider of differentiated specialty materials in life sciences and advanced technology end markets. With business operations in nine countries, Aceto distributes over 1,100 chemical compounds used principally by the pharmaceutical, nutraceutical, agricultural and specialty chemical industries.

A&C is a global GMP manufacturer of excipients, buffers, process solutions and a select number of active pharmaceutical ingredients. A&C has been servicing the global life sciences industry since 1966 and has offices and GMP production facilities in North America and Europe.

Osler, Hoskin & Harcourt LLP represented Aceto with a team consisting of
Shahir Guindi,
Matthew Oliver,
Véronique Fortin-Latreille (business law and M&A),
Julien Ranger (pensions and benefits),
Susan Newell (health),
Manon Thivierge (taxation),
Caroline Stephens (real estate),
Patrick Welsh (environment),
Sam Ip (technology),
Kelly Moffatt (commercial),
Natasha Anzik (privacy),
Danielle Chu (competition/antitrust and foreign investment).

McMillan LLP represented A&C with a team led by
Enda Wong (business law and M&A),
and which included
David Rosentzveig,
Evan Krakower,
Catherine Burrogano (business law and M&A),
Keith Hanna (financial services).